SEARCH

SEARCH BY CITATION

References

  • 1
    Wierzbicki AS. Niacin: the only vitamin that reduces cardiovascular events. Int J Clin Pract 2011; 65: 37985.
  • 2
    The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 36081.
  • 3
    AIM-HIGH investigators. AIM-HIGH: blinded treatment phase of study stopped. AIM-HIGH cholesterol management program 2011 May 26 [cited 2011 Jul 31]; Available from: URL: http://www.aimhigh-heart.com/
  • 4
    Wierzbicki AS. Surrogate markers, atherosclerosis and cardiovascular disease prevention. Int J Clin Pract 2008; 62: 9817.
  • 5
    Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 157789.
  • 6
    AIM-HIGH investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J 2011; 161: 4717.
  • 7
    AIM-HIGH investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. Am Heart J 2011; 161: 53843.
  • 8
    Wierzbicki AS. FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract 2006; 60: 4429.
  • 9
    Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 184961.
  • 10
    Wierzbicki AS. Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Curr Opin Lipidol 2010; 21: 3528.
  • 11
    Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 218192.
  • 12
    Rossebo AB, Pedersen TR, Boman K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 134356.
  • 13
    Wierzbicki AS, Viljoen A, Chambers JB. Aortic stenosis and lipids. Does intervention work? Curr Opin Cardiol 2010; 25: 37984.
  • 14
    Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 156374.
  • 15
    Wierzbicki AS, Morrell J, Hemsley D, McMahon Z, Crook MA, Wray R. The effect of fibrate-statin combination therapy on cardiovascular events: a retrospective cohort analysis. Curr Med Res Opin 2010; 26: 21416.
  • 16
    HPS2-THRIVE investigators. A randomized trial of the long-term clinical effects of raising HDL cholesterol with extended release niacin/laropiprant. Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE). ClinicalTrials gov 2009 February 2NCT00461630. Available from: URL: http://clinicaltrials.gov/ct2/show/NCT00461630
  • 17
    Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20: 125368.
  • 18
    Khera AV, Cuchel M, Llera-Moya M et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364: 12735.
  • 19
    Wierzbicki AS. Raising HDL-C: back to the future? Int J Clin Pract 2007; 61: 106971.
  • 20
    Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 210922.
  • 21
    Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999; 19: 18795.
  • 22
    Goldfine AB, Kaul S, Hiatt WR. Fibrates in the treatment of dyslipidemias — time for a reassessment. N Engl J Med 2011; 19: 4814.